Lineage Cell Therapeutics FY2028 EPS Cut by B. Riley

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Stock analysts at B. Riley lowered their FY2028 earnings per share (EPS) estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, August 15th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.15 for the year, down from their previous estimate of $0.20. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics’ FY2029 earnings at $0.11 EPS.

Other analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Thursday, August 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Lineage Cell Therapeutics currently has an average rating of “Buy” and a consensus target price of $4.20.

Lineage Cell Therapeutics Stock Up 6.7%

Shares of NYSEAMERICAN LCTX opened at $1.28 on Monday. The stock has a market capitalization of $292.30 million, a price-to-earnings ratio of -7.11 and a beta of 1.66. The stock’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $0.69. Lineage Cell Therapeutics has a 52-week low of $0.37 and a 52-week high of $1.31.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LCTX. Broadwood Capital Inc. grew its stake in shares of Lineage Cell Therapeutics by 18.9% in the first quarter. Broadwood Capital Inc. now owns 49,560,992 shares of the company’s stock worth $22,382,000 after purchasing an additional 7,894,737 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Lineage Cell Therapeutics in the fourth quarter worth $1,984,000. Comerica Bank grew its stake in shares of Lineage Cell Therapeutics by 275.0% in the first quarter. Comerica Bank now owns 3,000,000 shares of the company’s stock worth $1,355,000 after purchasing an additional 2,200,000 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock worth $1,147,000 after purchasing an additional 2,085,972 shares during the last quarter. Finally, DAFNA Capital Management LLC grew its stake in shares of Lineage Cell Therapeutics by 85.9% in the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock worth $1,262,000 after purchasing an additional 1,160,666 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.